CureVac N.V. (CVAC)
NASDAQ: CVAC · Real-Time Price · USD
3.190
0.00 (0.00%)
Apr 23, 2025, 4:00 PM EDT - Market closed
CureVac Employees
As of December 31, 2024, CureVac had 983 total employees, including 825 full-time and 158 part-time employees. The number of employees decreased by 189 or -16.13% compared to the previous year.
Employees
983
Change (1Y)
-189
Growth (1Y)
-16.13%
Revenue / Employee
$563,656
Profits / Employee
$170,816
Market Cap
718.25M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novartis AG | 75,883 |
CVAC News
- 13 days ago - CureVac N.V. (CVAC) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 13 days ago - CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2024 and Provides Business Update - Accesswire
- 15 days ago - CureVac to Report Fourth Quarter and Full-Year 2024 Financial Results and Business Update on April 10, 2025 - Accesswire
- 16 days ago - CureVac Receives U.S. FDA IND Clearance to Initiate Phase 1 Clinical Trial for Novel mRNA-Based Precision Immunotherapy in Squamous Non-Small Cell Lung Cancer - Accesswire
- 26 days ago - CureVac Shares Rise on Patent Confirmation Amid BioNTech Lawsuit - Market Watch
- 26 days ago - European Patent Office Rules Vaccine Developer CureVac's Amended Patent Valid, Stock Jumps - Benzinga
- 27 days ago - European Patent Office declares CureVac mRNA patent valid - Reuters
- 27 days ago - CureVac Receives Positive Validity Decision from European Patent Office in Litigation Against BioNTech SE - Accesswire